Patents by Inventor Sebastien Andre Campos

Sebastien Andre Campos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds
    Patent number: 10793559
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: October 6, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
    Patent number: 10730862
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 4, 2020
    Assignees: Yale University, Glaxosmithkline Intellectual Property Development, Cambridge Enterprise Limited University of Cambridge
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Denton Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • Chemical compounds
    Patent number: 10457674
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: October 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Niall Andrew Anderson, Nicholas Paul Barton, Sebastien Andre Campos, Edward Paul Cannons, Anthony William James Cooper, Kenneth David Down, Kevin James Doyle, Julie Nicole Hamblin, Graham George Adam Inglis, Armelle Le Gall, Vipulkumar Kantibhai Patel, Simon Peace, Andrew Sharpe, Gemma Victoria White
  • Compounds
    Patent number: 9993514
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 12, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre Campos, John David Harling
  • Benzothiophene derivatives as estrogen receptor inhibitors
    Patent number: 9988376
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 5, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre Campos, John David Harling, Afjal Hussain Miah, Ian Edward David Smith
  • Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
    Publication number: 20140356322
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Inventors: Craig M. Crews, Dennis Buckley, Alessio Ciulli, William Jorgensen, Peter C. Gareiss, Inge Van Molle, Jeffrey Gustafson, Hyun-Seop Tae, Julien Michel, Dentin Wade Hoyer, Anke G. Roth, John David Harling, Ian Edward David Smith, Afjal Hussain Miah, Sebastien Andre Campos, Joelle Le
  • Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
    Patent number: 8575181
    Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: November 5, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Sebastien Andre Campos, Diane Mary Coe, Naimisha Trivedi
  • PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES
    Publication number: 20110135670
    Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Application
    Filed: August 7, 2009
    Publication date: June 9, 2011
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Sebastien Andre Campos, Diane Mary Coe, Naimisha Trivedi
  • PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS
    Publication number: 20100179139
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 15, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis
    Patent number: 7687532
    Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: March 30, 2010
    Assignee: GlaxoSmithkline LLC
    Inventors: Sebastien Andre Campos, Stephen Swanson, Ann Louise Walker
  • PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS
    Publication number: 20100035917
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: February 11, 2010
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors
    Publication number: 20090023725
    Abstract: Compounds of formula (I): are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
    Type: Application
    Filed: January 27, 2005
    Publication date: January 22, 2009
    Inventors: Paul Bamborough, Sebastien Andre Campos, Vipulkumar Kantibhai Patel, Stephen Swanson, Ann Louise Walker
  • NOVEL COMPOUNDS
    Publication number: 20080176891
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: July 24, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth
  • NOVEL COMPOUNDS
    Publication number: 20080146606
    Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: June 19, 2008
    Inventors: Paul Bamborough, Michael David Barker, Sebastien Andre Campos, Richard Peter Charles Cousins, Paul Faulder, Heather Hobbs, Duncan Stuart Holmes, Michael John Johnston, John Liddle, Jeremy John Payne, John Martin Pritchard, Caroline Whitworth